Verve Therapeutics (NASDAQ:VERV) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Verve Therapeutics (NASDAQ:VERV) posted its earnings results on Thursday. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.14, Zacks reports. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.

Verve Therapeutics Trading Down 1.7 %

NASDAQ:VERV traded down $0.11 during trading hours on Thursday, hitting $6.20. 1,491,171 shares of the stock traded hands, compared to its average volume of 1,542,883. The firm has a 50 day moving average price of $6.87 and a 200 day moving average price of $5.98. Verve Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $19.34. The firm has a market cap of $524.92 million, a price-to-earnings ratio of -2.52 and a beta of 1.74.

Wall Street Analyst Weigh In

VERV has been the subject of several recent research reports. HC Wainwright lowered their target price on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Royal Bank of Canada reduced their price objective on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group boosted their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Verve Therapeutics currently has an average rating of “Buy” and an average price target of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.